This report was first published by Endpoints News. To see the original version, click here
GSK CEO Luke Miels laid out the drugmaker’s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir.
“We need to be more product-centric as a company,” Miels said Wednesday during GSK’s earnings call with the media. “So I can’t stress this enough: For us, accelerating R&D is our biggest opportunity to create value as a company.”
您已阅读16%（495字），剩余84%（2551字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。